Flash FinanceUS
After hours S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · TALPHERA, INC. (TLPH)

Talphera Q2 net loss widens to $4.3 million; cash and investments $17.1 million

Mixed Impact 3 of 5 earnings Written later

Talphera reported no revenue for the second quarter of 2026 and a net loss of $4.3 million, or $0.06 per share, versus a net loss of $3.5 million, or $0.10 per share, a year earlier. The dollar loss grew, but the per-share loss narrowed as weighted shares rose to 75.5 million from 34.5 million. The company said NEPHRO CRRT study enrollment reached 75%, with completion expected this year.

Key points

  • Net loss of $4.3 million, or $0.06 per share, for Q2 2026, compared with $3.5 million, or $0.10 per share, for Q2 2025
  • Combined R&D and SG&A expenses of $3.9 million, up from $3.7 million, mainly due to higher Niyad development expenses
  • Cash, cash equivalents and investments of $17.1 million at June 30, 2026, down from $20.4 million at December 31, 2025
  • NEPHRO CRRT study 75% enrolled; company regained Nasdaq compliance with the $1 bid price rule

The filing

CompanyTALPHERA, INC. (TLPH)
Form8-K, current report
Filed with the SECAug 12, 2026, 4:08 PM ET
Accession number0001437749-26-027311

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 10:08 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 12, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.